Abstract
Primary autoimmune cerebellar ataxia (PACA) is an idiopathic sporadic cerebellar ataxia that is thought to be immune-mediated but lacks biomarkers or a known cause. Here, we report two cases of immune-mediated cerebellar ataxia that responded favorably to immunotherapy, in which tissue-based indirect immunofluorescence test for serum or cerebrospinal fluid (CSF) samples yielded positive results. Case 1 was a 78-year-old man who presented with subacute progressive gait ataxia with truncal instability and dysarthria in response to steroids. Case 2 was a 62-year-old man who presented with relapses and remissions of acute progressive cerebellar ataxia occurring 1–2 times per year. Despite a favorable response to steroid treatment, he relapsed repeatedly in the absence of long-term immunosuppression. In the case of “idiopathic” cerebellar ataxia, immune-mediated causes should be investigated, and immunotherapy may have therapeutic effects.
Similar content being viewed by others
Data Availability
The original contributions generated for this study are included in the article, and further inquiries can be directed to the corresponding author/s.
Abbreviations
- ACA:
-
Autoimmune cerebellar ataxia;
- PCD:
-
Paraneoplastic cerebellar degeneration;
- PACA:
-
Primary autoimmune cerebellar ataxia;
- TBAs:
-
Tissue-based assays;
- CBAs:
-
Cell-based assays;
- IVIG:
-
Intravenous immunoglobulin;
- mRS:
-
Modified Rankin Scale;
- 18F-FDG PET/CT:
-
18F-fluorodeoxyglucose positron emission tomography /computed tomography
References
Mitoma H, Manto M, Hampe CS. Immune-mediated cerebellar ataxias: practical guidelines and therapeutic challenges. Curr Neuropharmacol. 2019;17(1):33–58. https://doi.org/10.2174/1570159x16666180917105033.
Jones AL, Flanagan EP, Pittock SJ, Mandrekar JN, Eggers SD, Ahlskog JE, et al. Responses to and outcomes of treatment of autoimmune cerebellar ataxia in adults. JAMA Neurol. 2015;72(11):1304–12. https://doi.org/10.1001/jamaneurol.2015.2378.
Mitoma H, Manto M, Hadjivassiliou M. Immune-mediated cerebellar ataxias: clinical diagnosis and treatment based on immunological and physiological mechanisms. J Mov Disord. 2021;14(1):10–28. https://doi.org/10.14802/jmd.20040.
Hadjivassiliou M, Boscolo S, Tongiorgi E, Grünewald RA, Sharrack B, Sanders DS, et al. Cerebellar ataxia as a possible organ-specific autoimmune disease. Mov Disord. 2008;23(10):1370–7. https://doi.org/10.1002/mds.22129.
Hadjivassiliou M, Graus F, Honnorat J, Jarius S, Titulaer M, Manto M, et al. Diagnostic criteria for primary autoimmune cerebellar ataxia-guidelines from an International Task Force on immune-mediated cerebellar ataxias. Cerebellum (London, England). 2020;19(4):605–10. https://doi.org/10.1007/s12311-020-01132-8.
Jarius S, Wildemann B. ‘Medusa-head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII. J Neuroinflammation. 2015;12:166. https://doi.org/10.1186/s12974-015-0356-y.
Jarius S, Wildemann B. ‘Medusa head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: Anti-PKC-gamma, anti-GluR-delta2, anti-Ca/ARHGAP26 and anti-VGCC. J Neuroinflammation. 2015;12:167. https://doi.org/10.1186/s12974-015-0357-x.
Jarius S, Wildemann B. ‘Medusa head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook. J Neuroinflammation. 2015;12:168. https://doi.org/10.1186/s12974-015-0358-9.
Masi G, Spagni G, Campetella L, Monte G, Sabatelli E, Evoli A, et al. Assessing the role of a tissue-based assay in the diagnostic algorithm of autoimmune encephalitis. Journal of neuroimmunology. 2021;356:577601. https://doi.org/10.1016/j.jneuroim.2021.577601.
Lee SK, Lee ST. The laboratory diagnosis of autoimmune encephalitis. J Epilepsy Res. 2016;6(2):45–50. https://doi.org/10.14581/jer.16010.
Hadjivassiliou M, Grunewald RA, Shanmugarajah PD, Sarrigiannis PG, Zis P, Skarlatou V, et al. Treatment of primary autoimmune cerebellar ataxia with mycophenolate. Cerebellum (London, England). 2020;19(5):680–4. https://doi.org/10.1007/s12311-020-01152-4.
Hadjivassiliou M, Grϋnewald RA. Gluten ataxia: an underdiagnosed condition. The Cerebellum. 2022;21(4):620–2. https://doi.org/10.1007/s12311-021-01270-7.
Guan WJ, Liu XJ, Tang BS, Liu YT, Zhou Y, Jiang H, et al. Gluten ataxia of sporadic and hereditary cerebellar ataxia in patients from mainland China. Neurol India. 2013;61(3):226–30. https://doi.org/10.4103/0028-3886.115056.
Liu M, Ren H, Zhu Y, Fan S, Bai L, Wang J, et al. Autoimmune cerebellar ataxia: etiology and clinical characteristics of a case series from China. The Cerebellum. 2022. https://doi.org/10.1007/s12311-022-01412-5.
Yoshikura N, Kimura A, Fukata M, Fukata Y, Yokoi N, Harada N, et al. Long-term clinical follow-up of a patient with non-paraneoplastic cerebellar ataxia associated with anti-mGluR1 autoantibodies. J Neuroimmunol. 2018;319:63–7. https://doi.org/10.1016/j.jneuroim.2018.04.001.
Ruiz-García R, Martínez-Hernández E, Joubert B, Petit-Pedrol M, Pajarón-Boix E, Fernández V, et al. Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. Neurol (R) Neuroimmunol Neuroinflammation. 2020;7(2):e658. https://doi.org/10.1212/nxi.0000000000000658.
Mitoma H, Hadjivassiliou M, Honnorat J. Guidelines for treatment of immune-mediated cerebellar ataxias. Cerebellum & ataxias. 2015;2:14. https://doi.org/10.1186/s40673-015-0034-y.
Greenlee JE. Treatment of paraneoplastic cerebellar degeneration. Curr Treat Options Neurol. 2013;15(2):185–200. https://doi.org/10.1007/s11940-012-0215-4.
Acknowledgements
We appreciate the patients’ consent to publish this information. We thank the State Key Laboratory of Translational Medicine and Innovative Drug Development, Ministry of Science and Technology, Jiangsu Simcere Diagnostics Co, Ltd for assistance with the autoimmune encephalitis-related test. The assistance of Dr. Wang Chunxia of Jiangsu Simcere Diagnostics in interpreting the TBA results is greatly appreciated. We thank Shanghai BioGerm Medical Technology Co., Ltd. and Vision Medicals Co., Ltd for their assistance with the sequencing test.
Funding
This research was funded by the Natural Science Foundation of Jiangsu Province for Distinguished Young Scholars (BK20200192), the Natural Science Research of Jiangsu Higher Education Institutions of China (20KJD320007), and the Suzhou Municipal Science and Technology Bureau (KJXW2019012). The role of the funding body was in the collection and interpretation of data and drafted the manuscript.
Author information
Authors and Affiliations
Contributions
JL and BD assessed the patient, conceived the research concept, and authored the initial manuscript. Participating in the clinical management were KL, WS, JA, XL, HZ, YZ, and WZ. The paper was edited by GS and CL for its intellectual substance. The final paper was reviewed and approved by XC and YZ. All authors participated to and approved the final draft of the article. JL and BD contributed equally as co-first authors to this study. XC and YZ contributed equally as co-correspondence authors to this work.
Corresponding authors
Ethics declarations
Ethical Approval and Consent to Participate
The clinical trial was approved by the ethics committee of The Second Affiliated Hospital of Soochow University (JD-LK-2021–079-02) and the ethical committee of Huashan Hospital Affiliated to Fudan University (KY 2021–451) and was registered in ClinicalTrial.gov of Optimal Encephalitis/Meningitis Roadmap Via Precise Diagnosis and Treatment (IMPROVE, NCT04946682).
Consent for Publication
Written informed consent was obtained from the individual for the publication of any potentially identifiable images or data included in this article.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Li, J., Deng, B., Song, W. et al. Immunotherapies for the Effective Treatment of Primary Autoimmune Cerebellar Ataxia: a Case Series. Cerebellum 22, 1216–1222 (2023). https://doi.org/10.1007/s12311-022-01496-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12311-022-01496-z